TNFRSF12A and cancer: Since TWEAK might promote cancer cell survival, a monoclonal antibody developed to block the TWEAK receptor (enabatuzumab) is being tested clinically in cancer trials (Lam and others 2018), although it has possible hepatotoxic effects.